PRISM Neurology Series · RWID Multimodal
Amyloid-Targeting Therapies - Brain Imaging Longitudinal Dataset
A longitudinal, patient-level dataset designed to monitor amyloid-related imaging abnormalities (ARIA) in patients treated with anti-amyloid therapies such as Lecanemab and Donanemab, integrating serial brain MRI, treatment exposure, cognitive scores, and clinical outcomes with precise temporal alignment.
Axial brain MRI (FLAIR - Fluid-Attenuated Inversion Recovery) used for ARIA monitoring in anti-amyloid therapy. De-identified.
540
Brain MRI studies in the cohort
3
MR scanner brands
2017–25
Time frame coverage
Quarterly
Data refresh cycle
Dataset Specifications
What is in the PRISM Amyloid-Targeting Therapies Brain Imaging Dataset
Serial brain MRI linked to treatment exposure, cognitive assessments, and clinical outcomes, with precise temporal alignment between drug administration, imaging, and ARIA events.
Therapeutic Area
Neurology
Disease Focus
Alzheimer's disease · Mild Cognitive Impairment (MCI) due to Alzheimer's disease · Mild Alzheimer's dementia
Treatment Types
Anti-amyloid β monoclonal antibodies (disease-modifying therapies)
Imaging Modalities
Brain MRI (serial, including ARIA-E and ARIA-H structured findings) · Amyloid PET · Tau PET
Clinical Data (EHR)
Demographics · baseline disease characteristics · APOE ε4 status · treatment exposure (dose, infusion dates, interruptions) · cognitive scores (MMSE, MoCA, CDR/CDR-SB, ADAS-Cog, NPI, FAQ) · hospitalizations
Data Sources
Neurology · pharmacy dispensing · radiology (DICOM) · nuclear medicine (DICOM) · laboratory
Data Format & Compliance
DICOMs and structured ARIA findings (severity, timing, resolution) · HIPAA de-identified · Provenance documentation built into acquisition · Precise temporal alignment between drug administration, imaging, and clinical events
Therapies Presented
Anti-amyloid therapies in the cohort
The dataset covers patients receiving approved anti-amyloid monoclonal antibodies, enabling comparative safety and ARIA profiling across therapies.
Lecanemab
Leqembi®: Anti-amyloid β monoclonal antibody. Biweekly IV infusion. 65 patients with pre- and post-treatment brain MRI in the cohort.
Donanemab
Kisunla®: Anti-amyloid β monoclonal antibody. Monthly IV infusion. Dosing until amyloid clearance. 7 patients with pre- and post-treatment brain MRI in the cohort.
Applications
What this dataset enables
From imaging biomarker validation to real-world safety surveillance and AI model development for anti-amyloid therapies.
Imaging biomarkers and treatment response
MRI biomarkers include whole brain volume, hippocampal volume, cortical thickness, and white matter disease burden. Evaluate whether anti-amyloid therapy changes structural progression.
MRI surveillance optimization
Investigate personalized monitoring approches, e.g., wheter low-risk patients could undergo fewer scans.
Real-world protocol adherence
Discover how management guidelines are followed in real-world clinical practice across institutions.
Effectiveness in expanded populations
Discover how management guidelines are followed in real-world clinical practice across institutions.
Radiology AI model development
Automated detection and reporting of superficial siderosis, microbleeds, ARIA.
Predictive models development
Models for cognitive trajectory, safety, treatment discontinuation, and more!
Biomarkers & Endpoints
Key biomarkers, endpoints, and clinical variables
Imaging findings, cognitive assessments, and treatment exposure data with precise temporal alignment. Variable selection is tailored to your programme's safety, efficacy, or regulatory objectives.
ARIA Imaging Findings
- ARIA-E (edema/effusion): presence, severity, timing
- ARIA-H (microhemorrhage): presence, count, severity
- Superficial siderosis: presence, extent
- ARIA resolution status and timing
- Serial brain MRI structural findings
Cognitive Assessments
- Mini-Mental State Examination (MMSE)
- Montreal Cognitive Assessment (MoCA)
- Clinical Dementia Rating (CDR / CDR-SB)
- Alzheimer's Disease Assessment Scale, Cognitive (ADAS-Cog)
- Neuropsychiatric Inventory (NPI)
- Functional Activities Questionnaire (FAQ)
* per routine clinical care at the discretion of the care team
Treatment Exposure
- Drug and dose
- Complete infusion dates (all sessions)
- Treatment interruptions and reasons
- Duration on therapy
- Discontinuation status
Baseline & Clinical
- APOE ε4 status
- Disease stage (MCI vs. mild AD)
- Demographics (age, sex, race, ethnicity)
- Hospitalizations
- Patient-reported outcomes
- Cognitive trajectory over time
Dataset Request
Request access to PRISM Series RWID Multimodal Cohorts
Receive technical specifications for the pre-built research cohort relevant to your programme.
